1 / 17

The University of Texas M.D . Anderson Cancer Center, Houston, TX

A Phase II Study of Capecitabine and Oxaliplatin with Concurrent Radiation Therapy (XELOX-XRT) in Squamous Cell Carcinoma Of The Anal Canal. C. Eng 1 , G. J. Chang 2 , P. Das 3 , M. Rodriguez-Bigas 2 , J. M. Skibber 2 , W. Qiao 4 , G. L. Rosner 4 ,

jerome
Download Presentation

The University of Texas M.D . Anderson Cancer Center, Houston, TX

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Phase II Study of Capecitabine and Oxaliplatin with Concurrent Radiation Therapy (XELOX-XRT) in Squamous Cell Carcinoma Of The Anal Canal C. Eng1, G. J. Chang2, P. Das3, M. Rodriguez-Bigas2, J. M. Skibber2, W. Qiao4, G. L. Rosner4, L. T. Ukegbu1, R. A. Wolff1, C.H. Crane3 Department of Gastrointestinal Medical Oncology1, Department of Surgical Oncology2, Department of Radiation Oncology3, Department of Biostatistics4 The University of Texas M.D. Anderson Cancer Center, Houston, TX

  2. BACKGROUND • Anal cancer accounts for 1.5% of all digestive system malignancies in the United States.1 • Squamous cell carcinoma (SCC) represents approximately 80% of all anal cancers.2 • Greater than 90% of patients will present with locoregional disease that is treated with concurrent chemoradiation therapy with curative intent reserving abdominal perineal resection (APR) for salvage surgery. • Risk factors for anal carcinoma include HPV infection and chronic immunosuppression. • The treatment paradigm of anal carcinoma has remained unchanged for the past three decades.

  3. BACKGROUND(cont’d.) • Traditionally, 5-FU based combinations with mitomycin C (MMC) are provided with concurrent radiation therapy but may result in significant and dose-limiting hematologic toxicities 3. 5-FU with cisplatin has also been investigated. • The use of capecitabine rather than continuous infusion 5-FU may allow increased convenience without compromising synergy with radiation therapy. • Oxaliplatin has radiosensitization properties, and a favorable toxicity profile relative to MMC or cisplatin. 3 • To date, the role of oxaliplatin and capecitabine in squamous cell carcinoma of the anal canal has not been reported.

  4. Rationale • The use of oral capecitabine rather than infusional intravenous 5-FU allows increased convenience. • The radiosensitizing properties of oxaliplatin, its improved toxicity profile relative to cisplatin, and its synergism with 5-FU validates further analysis as a radiation sensitizer. • The combination of capecitabine and oxaliplatin(XELOX) has been determined to be feasible in the palliative treatment of metastatic colorectal cancer but also in combined modality therapy with radiation in the treatment of rectal cancer. • Hence, XELOX-XRT, may result in equivalent or decreased toxicities to that of the traditional regimen of IV 5-FU with mitomycin C or cisplatin without compromising efficacy.

  5. Objectives • Primary Objectives: • Determine time to treatment failure: • Defined as: • Disease persistence or progression • Disease recurrence • Treatment-related mortality • Determine treatment-related toxicities: • Defined as: • > Grade 3 gastrointestinal symptoms • Grade 4 radiation-induced dermatitis • >Grade 3 hematologic or nonhematologic toxicity (excluding radiation dermatitis) • Toxicities resulting in treatment delays > 7 days • Secondary Objectives: • Rate of complete response (CR) • Rate of locoregional control (LCR) • Two-year rates of: • Colostomy-free survival • Overall survival • Progression-free survival

  6. Study Design • Single institution Phase II study to evaluate the efficacy and safety of capecitabine and oxaliplatin with concomitant radiation therapy (XELOX-XRT) in patients with previously untreated locally advanced squamous cell carcinoma of the anal canal. • Interim safety analysis using Bayesian stopping rules: Toxicity and failure-free survival was evaluated after every 10 patients and was initiated three months after the 10th patient enrolled.   • Further study will be pursued if 4-yr failure-free survival is not worse than 73% and risk of acute toxicity is < 45%. • Early stopping rule: > 80% probability that the risk of acute toxicity is > 35%

  7. Eligibility Criteria • Histologically proven SCCA of the anal canal • AJCC stage II-IIIB (T1-4 NxM0 or TxN1-3 M0) • ECOG PS 0-1 • Informed consent • No prior radiation to the pelvis • No prior surgery for anal carcinoma excluding biopsy • No peripheral neuropathy > CTC Grade 2 (Ver 3.0) • Treatment naïve to oxaliplatin or 5-FU-based therapy • No need for anticoagulation with coumadin • HIV (+) patients were ineligible

  8. Treatment Regimen(Chemotherapy) • Chemotherapy initially consisted of capecitabine (825 mg/m2BID, M-F) and weekly oxaliplatin (50 mg/m2) (Group 1) subsequently modified due to treatment-related diarrhea to omission of chemotherapy during weeks 3 and 6 (Group 2).

  9. Treatment Regimen(Radiotherapy)

  10. Evaluation

  11. Results • 20 patients were enrolled. All patients were evaluable for toxicity; 19 for response. • Five of the first 11 patients (Group 1) developed grade 3 treatment-related diarrhea (Table 2). The regimen was then modified for the subsequent 9 patients (Group 2), of whom only one patient developed diarrhea. Table 1

  12. Toxicities of Interest • Table 2

  13. Adverse Events by Maximum Grade

  14. Response Rates • Complete response rates of the primary tumor were 100% in Group 1 and 100% in Group 2, respectively. • One patient in Group 1 developed distant disease to the liver 10 months after the completion of chemoradiation therapy. • One patient developed a second microscopic primary SCCA of the anal canal (<1mm focus), 3.5 yrs after completing initial therapy. He was treated with chemoradiation therapy and remains disease-free. • Based on the log-rank test (p=0.4), there was no significant difference between the two treatment groups regarding time to treatment failure. (Graph1)

  15. Kaplan Meier Failure Free Survival • Based on the log-rank test (p=0.4), there was no significant difference between the two treatment groups regarding time to treatment failure

  16. Conclusions • Capecitabine and oxaliplatin with concurrent radiation therapy is an effective approach in the treatment of locally advanced squamous cell carcinoma of the anal canal. • Weekly chemotherapy administration resulted in increased toxicity (predominately grade 3 diarrhea). Omission of chemotherapy weeks 3 and 6 decreased toxicity without compromising efficacy of therapy. • After a median follow up of 2 years, no patient has developed a local recurrence or required salvage resection with colostomy for a colostomy-free survival rate of 100%. • XELOX-XRT is feasible and an apparently effective approach for locally advanced squamous cell carcinoma of the anal canal and warrants further investigation.

  17. References • Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26. • Bendell JC, Ryan DP. Current perspectives on anal cancer. Oncology (Huntingt) 2003; 17:492-7, 502-3; discussion 503, 507-9. • Ajani et al. A phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal.. JAMA , April 23; 299(16), 1914-21, 2008

More Related